ArticleThe Lancet regional health. Western Pacific2023

Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial.

Yong Huo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.